Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 3
1950 2
1957 1
1963 2
1967 1
1968 1
1974 1
1975 1
1976 1
1979 3
1982 2
1983 1
1985 1
1987 4
1988 3
1989 3
1990 1
1991 9
1992 8
1993 2
1994 8
1995 5
1996 6
1997 7
1998 7
1999 9
2000 10
2001 7
2002 6
2003 12
2004 10
2005 13
2006 10
2007 19
2008 17
2009 14
2010 13
2011 18
2012 20
2013 21
2014 28
2015 24
2016 29
2017 22
2018 23
2019 13
2020 21
2021 33
2022 23
2023 14
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

475 results

Results by year

Filters applied: . Clear all
Page 1
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.
Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernández-Ávila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, Leung YY, Lindsay C, Lubrano E, Mazzuoccolo LD, Mease PJ, O'Sullivan D, Ogdie A, Olsder W, Palominos PE, Schick L, Steinkoenig I, de Wit M, van der Windt DA, Kavanaugh A; GRAPPA Treatment Recommendations domain subcommittees. Coates LC, et al. Among authors: helliwell ps. Nat Rev Rheumatol. 2022 Aug;18(8):465-479. doi: 10.1038/s41584-022-00798-0. Epub 2022 Jun 27. Nat Rev Rheumatol. 2022. PMID: 35761070 Free PMC article. Review.
Psoriatic arthritis: state of the art review.
Coates LC, Helliwell PS. Coates LC, et al. Among authors: helliwell ps. Clin Med (Lond). 2017 Feb;17(1):65-70. doi: 10.7861/clinmedicine.17-1-65. Clin Med (Lond). 2017. PMID: 28148584 Free PMC article. Review.
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Berekmeri A, et al. Among authors: helliwell p. Expert Rev Clin Immunol. 2018 Sep;14(9):719-730. doi: 10.1080/1744666X.2018.1512404. Expert Rev Clin Immunol. 2018. PMID: 30118353 Free article. Review.
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT; DISCOVER-1 Study Group. Deodhar A, et al. Among authors: helliwell ps. Lancet. 2020 Apr 4;395(10230):1115-1125. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178765 Free article. Clinical Trial.
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, Ostor A, Peeva E, Vincent MS, Sun Q, Sikirica V, Winnette R, Qiu R, Li G, Feng G, Beebe JS, Martin DA. Mease P, et al. Among authors: helliwell p. Arthritis Rheumatol. 2023 Aug;75(8):1370-1380. doi: 10.1002/art.42519. Epub 2023 Jun 22. Arthritis Rheumatol. 2023. PMID: 37194394 Free article. Clinical Trial.
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Xu S, Quinn ST, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar A, Østergaard M, Baraliakos X. Gladman DD, et al. Among authors: helliwell ps. Trials. 2022 Sep 5;23(1):743. doi: 10.1186/s13063-022-06589-y. Trials. 2022. PMID: 36064592 Free PMC article.
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, Burgos-Vargas R, Erickson JS, Rathmann SS, Sprabery AT, Birt JA, Shuler CL, Gallo G. Chandran V, et al. Among authors: helliwell ps. Rheumatology (Oxford). 2020 Oct 1;59(10):2774-2784. doi: 10.1093/rheumatology/kez684. Rheumatology (Oxford). 2020. PMID: 32031665 Free PMC article. Clinical Trial.
475 results